The SemaglutideGLPOne.com editorial team: three independent physicians overseeing all medical content, methodology, and ranking decisions. Editor-in-Chief Terra Walman M.D.; Clinical Accuracy Reviewer Michael Baghdassarian M.D.; Senior Medical Editor Joseph Safer M.D.
SemaglutideGLPOne.com is published by Publisher Partners LLC. The editorial operation is run by three independent physicians — all board-certified, all licensed, all independent from any reviewed provider. Each is profiled below with credentials, role responsibilities, and conflicts-of-interest disclosure.
Oversees all commercial editorial content, methodology, and ranking decisions. Specialty focus: GLP-1 receptor agonist therapy, obesity medicine, telehealth-delivered chronic care.
Full bio →
Reviews every medical, regulatory, and clinical claim on the site for accuracy. Independent from NexLife's clinical operation. Final clinical sign-off on all published content.
Full bio →
Senior editorial oversight on clinical pharmacology, dosing protocols, drug interactions, and titration content. Schema and structured-data review.
Full bio →
Every medical article on SemaglutideGLPOne goes through three independent reviews before publication:
None of the three editorial team members has financial relationships with any provider reviewed on this site, including NexLife. NexLife's Medical Director — Adam Kennah, M.D. — is a separate individual at a separate organization. We profile Dr. Kennah publicly for transparency because NexLife is the editor's #1 ranked provider, but he is not on our editorial team.
Each editorial team member's licensure is independently verifiable through the Federation of State Medical Boards (FSMB) DocInfo lookup at fsmb.org/spex/. Patients and journalists can verify license status, disciplinary history, and specialty board certifications independently.